What Happened? – KRW 5.4 Billion Supply Contract with Doosan
Pharmcell has secured a KRW 5.4 billion contract with Doosan Electronics BG to supply electronic materials. The contract period spans from August 21st to October 31st, 2025, representing approximately 8.33% of Pharmcell’s accumulated revenue in 2024.
Why Does It Matter? – Reaffirms Bio-Chemical Division’s Growth Momentum
Following a previous KRW 11.7 billion contract in December 2024, this new agreement underscores the continued growth of Pharmcell’s Bio-Chemical division. The ongoing collaboration with Doosan in electronic materials strengthens Pharmcell’s market competitiveness and enhances its future growth potential.
What’s Next? – Expected 2025 Performance Improvement & Long-term Growth
This contract is projected to contribute directly to Pharmcell’s revenue in the second half of 2025, solidifying the growth of its Bio-Chemical division, which achieved profitability in 2024. Additionally, the appreciating KRW exchange rate is expected to generate positive foreign exchange gains for Pharmcell, given its high export ratio.
Investor Action Plan – Monitor Further Contracts and Drug Development
Investors should closely monitor potential follow-up contracts with Doosan and the progress of new drug development within Pharmcell’s Bio-Medical division. Focusing on the company’s long-term growth potential, rather than short-term stock price fluctuations, is crucial.